Since 2000 there have been major advances in our understanding of the genetic and
genomics of pulmonary arterial hypertension (PAH), although there remains much to …

Vascular smooth muscle cells (VSMCs) are integral to the pathophysiology of cardiovascular
diseases (CVDs). Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a …

Rationale: Endothelial dysfunction plays an integral role in pulmonary hypertension (PH).
AMPK (AMP-activated protein kinase) and ACE2 (angiotensin-converting enzyme 2) are …

Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects
the survival of aerobic species and plays a prominent role in cardiovascular diseases. From …

Epigenetic mechanisms represent potential molecular routes which could bridge the gap
between genetic background and environmental risk factors contributing to the …

Background: Epigenetic mechanisms are critical in the pathogenesis of pulmonary arterial
hypertension (PAH). Previous studies have suggested that hypermethylation of the BMPR2 …

Pulmonary hypertension is a complex disease with multiple causes, corresponding to
phenotypic heterogeneity and variable therapeutic responses. Advancing understanding of …

DNA methylation plays critical roles in vascular pathology of pulmonary hypertension (PH).
The underlying mechanism, however, remains undetermined. Here, we demonstrate that …

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of
multifactorial etiology. Most of the available drugs and FDA-approved therapies for treating …

Pathogenic DNA methylation changes may be involved in pulmonary arterial hypertension
(PAH) onset and its progression, but there is no data on potential associations with patient …